

Contents lists available at [ScienceDirect](http://ScienceDirect)

## Asian Pacific Journal of Tropical Medicine

journal homepage: [www.elsevier.com/locate/apjtm](http://www.elsevier.com/locate/apjtm)

Document heading doi:

# Relationship between brain-derived neurotrophic factor and cognitive function of obstructive sleep apnea/hypopnea syndrome patients

Wei-Hong Wang<sup>1\*</sup>, Guo-Ping He<sup>2</sup>, Xu-Ping Xiao<sup>3</sup>, Can Gu<sup>2</sup>, Hua-Ying Chen<sup>1</sup><sup>1</sup>Medical College of Hunan Normal University, No. 371 Tongzipo Road, Changsha, Hunan 410013, People's Republic of China<sup>2</sup>School of Nursing, Central South University, Changsha, People's Republic of China<sup>3</sup>First Affiliated Hospital, Hunan Normal University, Changsha, People's Republic of China

## ARTICLE INFO

## Article history:

Received 10 June 2012

Received in revised form 15 August 2012

Accepted 15 September 2012

Available online 20 December 2012

## Keywords:

Obstructive sleep apnea/hypopnea syndrome

Cognitive function

Brain-derived neurotrophic factor

Sleep

## ABSTRACT

**Objective:** To determine the relationship between the blood serum brain-derived neurotrophic factor (BDNF) level and cognitive function deterioration in patients with obstructive sleep apnea/hypopnea syndrome (OSAHS), and to explore the possible mechanism of cognitive impairment.

**Methods:** Twenty-eight male OSAHS patients and 14 normal males (as controls) were enrolled in the study. Polysomnography and the Montreal cognitive assessment (MoCA) were conducted. The blood serum BDNF levels were measured using ELISA. **Results:** The OSAHS group had significantly decreased blood serum BDNF levels compared with the control group ( $t = -10.912$ ,  $P = 0.000$ ). The blood serum BDNF level of the subjects was significantly positively associated with the MoCA score ( $r = 0.544$ ,  $P = 0.000$ ), significantly negatively associated with the apnea-hypopnea index (AHI) and shallow sleep (S1+S2) (AHI:  $r = -0.607$ ,  $P = 0.000$ ; S1+S2:  $r = -0.768$ ,  $P = 0.000$ ), and significantly positively associated with the lowest SaO<sub>2</sub> (LSO), slow wave sleep (S3+S4), and rapid eye movement sleep (REM) (LSO:  $r = 0.566$ ,  $P = 0.000$ ; S3+S4:  $r = 0.778$ ,  $P = 0.000$ ; REM:  $r = 0.575$ ,  $P = 0.000$ ). **Conclusions:** OSAHS patients have significantly decreased blood serum BDNF levels compared with the control. Nocturnal hypoxia as well as the deprivation of slow wave sleep and REM may lead to the decreased serum BDNF level of OSAHS patients. This decreased blood serum BDNF level may contribute to the cognitive impairment in OSAHS.

## 1. Introduction

Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a common, serious disease characterized by complete or partial upper airway closure during sleep that results in periodic nocturnal oxyhemoglobin desaturation and sleep fragmentation. OSAHS commonly affects the cardiovascular, nervous, and endocrine systems, among others. Cognitive impairment is the major complication of the nervous

system in OSAHS. Studies showed that this condition can cause adult dementia<sup>[1]</sup>. Sleep fragmentation, repetitive nocturnal hypoxemia, and daytime sleepiness are suggested to contribute to the cognitive deficit in OSAHS<sup>[2]</sup>. However, although some researchers believe that this hypothesis can be proven by further experiments<sup>[3]</sup>, how these factors affect cognition is unclear.

Brain-derived neurotrophic factor (BDNF) is a protein produced by brain tissues. BDNF is the most abundant and widely distributed member of the neurotrophic factor family<sup>[4]</sup>. A number of studies proved the importance of BDNF in the differentiation, development, growth, and regeneration of the nervous system<sup>[5,6]</sup>. BDNF is also suggested to be closely associated with cognition. Li *et al*<sup>[7]</sup> reported that age-related cognitive decline (ARCD) patients have significantly decreased serum blood BDNF

\*Corresponding author: Wei-Hong Wang, Medical College of Hunan Normal University, No. 371 Tongzipo Road, Changsha, Hunan 410013, People's Republic of China.

E-mail: wangweihong3001@163.com

Foundation Project: This study was supported by the Science and Technology Bureau of Hunan Province, People's Republic of China (grant number 2011-FJ3192).

levels compared with healthy people. Caccamo *et al*[8,9] found that BDNF is correlated with cognitive impairment in Alzheimer's disease (AD) and type 2 diabetes mellitus (DM) patients. Several studies have demonstrated the relationship of BDNF with cognitive impairment in OSAHS, but the results are inconsistent. Wang *et al* reported that OSAHS children with cognitive impairment whose blood serum BDNF levels were significantly decreased compared with the control group[10]. Another study on adult OSAHS patients with cognitive deficit carried out by Hu *et al* had similar results[11]. Staats *et al* suggested that there is no significant difference in serum and plasma BDNF level between OSAHS patients and control group[12]. In the present study, we hypothesized that the serum BDNF level of OSAHS patients changed compared with healthy people and it related with their cognitive function. Thus, we determined the blood serum BDNF levels of middle-aged OSAHS men as well as explored the relationship of their cognitive deficit with sleep fragmentation and hypoxia/hypopnea to offer new clues to the mechanism of cognitive impairment in OSAHS patients.

## 2. Materials and methods

### 2.1. Subjects

From February 2011 to October 2011, 28 Han Chinese OSAHS male patients and 14 healthy volunteers aged 40–49 years were recruited to participate in this controlled, randomized, open-labeled study at the First Affiliated Hospital of Hunan Normal University. The inclusion criteria for OSAHS patients were as follows: newly diagnosed OSAHS by polysomnography according to standard criteria[13], apnea-hypopnea index (AHI)  $\geq 5$  without any previous therapy, and educational attainment higher than middle school. The exclusion criteria were as follows: history of chronic obstructive pulmonary disease, cardiovascular disease, hematological disorders, nephritic disease, nervous system diseases and injury, as well as diseases of the endocrine system; abnormal hepatic function; history of taking hormones, sedatives, and antipsychotics, as well as excessive drinking ( $>80$  g/d); and concurrent oncologic diseases.

The control group comprised individuals who were proved to be healthy and OSAHS free by polysomnography (PSG) and medical examination.

This study was approved by the Ethics Committee of Hunan Normal University. Written informed consent was obtained from all participants before the start of the study.

### 2.2. Treatments

#### 2.2.1. PSG

OSAHS was diagnosed using PSG. OSAHS was defined based on the American Association of Sleep Disorder standards.

Within 24 h before PSG, the subjects were not allowed to take sedatives as well as drink alcohol, tea, and coffee. They were put to sleep for 7.5 h from 10:30 pm to 6:00 am. The main indicators of PSG included AHI, lowest SaO<sub>2</sub> (LSO), duration of sleep stage I (S1) (%), sleep stage II (S2) (%), sleep stage III (S3) (%), sleep stage IV (S4) (%), and rapid eye movement sleep (REM) (%). The PSG results were examined and approved by the same doctor in the sleep center.

#### 2.2.2. Cognitive function

Cognitive function was evaluated using the Montreal cognitive assessment (MoCA) that evaluates executive function, naming, attention, calculation, language, abstraction, memory, and orientation. The total MoCA score is 30. A total MoCA score  $<26$  indicates cognitive impairment, whereas a score  $\geq 26$  indicates normal cognitive function. If the schooling length of the subject was less than 12 years, 1 point was added to the total score to adjust for educational bias[14]. The PSG lasted for 10 min.

#### 2.2.3. Serum sample collection and BDNF measurement

From 6:30 am to 7:00 am, 3 mL of blood was collected from the cubital veins before breakfast on the morning after PSG monitoring. Blood was allowed to coagulate for 10–20 min at room temperature and centrifuged for about 20 min (3 000 rpm). Serum was collected and stored in a refrigerator at  $-80$  °C. BDNF was measured using an enzyme-linked immunosorbent assay kit purchased from R&D.

### 2.3. Statistical analysis

Statistical analyses were performed using SPSS 17.0 for Windows. For continuous variables, all values were expressed as mean  $\pm$  standard deviation. The means between two groups were compared using the *t* test. Pearson correlation coefficient analysis was performed for variable correlation. The statistical significance level was set at two-sided  $\alpha = 0.05$ .

## 3. Results

Twenty-eight male OSAHS patients aged 40–49 years [average =  $(44.93 \pm 2.98)$  years] participated in this study. All subjects had educational attainments higher than middle school, with an average length of education of  $(14.43 \pm 1.99)$  years. The maximal, minimal, and average body mass indices (BMI) were 34.80, 21.71, and  $(28.69 \pm 3.70)$  kg/m<sup>2</sup>. Fourteen healthy male volunteers aged 40–49 years [average =  $(44.79 \pm 2.58)$  years] were included in the study. All volunteers had educational attainments higher than middle school, with an average length of education of  $(14.43 \pm 1.99)$  years. The maximal, minimal, and average BMIs were 33.10, 23.38, and  $(27.42 \pm 2.80)$  kg/m<sup>2</sup>, respectively. No significant difference was found in the age, schooling length, and BMI

between the OSAHS and control groups (Table 1). These results indicated that the study groups had comparable baseline data.

The OSAHS group had significantly higher AHI than the control group (Table 2). LSO was significantly decreased, and shallow sleep (S1+S2) was significantly extended in the OSAHS group. Slow wave sleep (S3+S4) and REM were also significantly reduced.

**Table 1**

Baseline socio-demographic characteristics of the OSAHS and control groups.

| Characters                  | OSAHS group(n=28) | Control group(n=14) | <i>t</i> | <i>P</i> |
|-----------------------------|-------------------|---------------------|----------|----------|
| Age (years)                 | 44.93±2.98        | 44.79±2.58          | 0.153    | 0.879    |
| Length of schooling (years) | 14.43±1.99        | 14.21±1.76          | 0.341    | 0.735    |
| BMI (kg/m <sup>2</sup> )    | 28.69±3.70        | 27.42±2.80          | 1.124    | 0.268    |

**Table 2**

Conditions of sleep and respiration of the OSAHS and control groups (mean±SD).

| Indexes       | OSAHS group(n=28) | Control group(n=14) | <i>t</i> | <i>P</i> |
|---------------|-------------------|---------------------|----------|----------|
| AHI (times/h) | 49.63±28.56       | 2.27±1.21           | 8.757*   | 0.000    |
| LSO (%)       | 67.92±12.66       | 89.64±5.95          | -7.556   | 0.000    |
| S1+S2 (%)     | 76.75±6.33        | 25.96±6.82          | 23.899   | 0.000    |
| S3+S4 (%)     | 10.24±2.84        | 37.36±12.76         | -7.859*  | 0.000    |
| REM (%)       | 5.78±2.71         | 22.02±5.51          | -10.411  | 0.000    |

Note: \**t'* value.

Table 3 shows that the OSAHS group had significantly decreased total MoCA scores as well as scores of executive function, calculation, abstraction, and memory compared with the control group (*P* < 0.05).

The mean serum BDNF level of the OSAHS group was (5.01±0.61) ng/mL, whereas that of the control group was (7.27±0.68) ng/mL. The serum BDNF level of the OSAHS patients were significantly decreased compared with the control group (*t* = -10.912, *P* = 0.000).

**Table 3**

Cognitive function of the OSAHS and control groups (mean±SD).

| Cognitive function | OSAHS group (n = 28) | Control group (n = 14) | <i>t</i> | <i>P</i> |
|--------------------|----------------------|------------------------|----------|----------|
| Total MoCA score   | 24.04±1.75           | 28.57±1.09             | -8.835   | 0.000**  |
| Executive function | 3.39±0.92            | 4.86±0.36              | -7.375   | 0.000**  |
| Naming             | 2.79±0.42            | 2.86±0.53              | -0.475   | 0.637    |
| Attention          | 2.39±0.49            | 2.57±0.51              | -1.085   | 0.284    |
| Calculation        | 2.54±0.51            | 2.86±0.36              | -2.355   | 0.024*   |
| Language           | 2.54±0.74            | 2.71±0.47              | -0.817   | 0.419    |
| Abstraction        | 1.61±0.50            | 2.14±0.36              | -3.965   | 0.000**  |
| Memory             | 3.14±0.76            | 4.50±0.52              | -6.027   | 0.000**  |
| Orientation        | 5.57±0.50            | 5.79±0.43              | -1.444   | 0.159    |

Note: \**P* < 0.05, \*\**P* < 0.01.

Table 4 shows that the total MoCA score of the subjects was significantly positively associated with the blood serum BDNF level (*r* = 0.544, *P* = 0.000) (Table 4). The scores of executive function (*r* = 0.550, *P* = 0.000), abstraction (*r* = 0.408, *P* = 0.007), and memory (*r* = 0.509, *P* = 0.001) were also significantly positively associated with the blood serum BDNF level. The serum BDNF level had no significant difference from the age, BMI, and schooling length.

Table 5 shows that the serum BDNF level had no correlation with the age, BMI, and schooling length. The serum BDNF level was significantly negatively correlated with the AHI and S1+S2, but significantly positively correlated with the LSO, S3+S4, and REM.

**Table 4**

Correlation of the MoCA score with the age, BMI, schooling length, and blood serum BDNF level.

| Indexes            | Age    | BMI    | Schooling length | BDNF (ng/mL) |
|--------------------|--------|--------|------------------|--------------|
| Total MoCA score   | -0.307 | -0.274 | 0.113            | 0.544**      |
| Executive function | -0.295 | -0.243 | 0.197            | 0.550**      |
| Naming             | -0.219 | -0.138 | 0.140            | 0.176        |
| Attention          | -0.040 | -0.302 | 0.184            | 0.047        |
| Calculation        | -0.289 | -0.010 | 0.152            | 0.162        |
| Language           | -0.090 | -0.176 | -0.025           | 0.039        |
| Abstraction        | 0.238  | -0.087 | -0.307           | 0.408**      |
| Memory             | -0.088 | -0.063 | -0.064           | 0.509**      |
| Orientation        | 0.095  | -0.211 | -0.163           | 0.047        |

Note: All values in the table are expressed as *r*. Pearson correlation coefficient analysis was performed to analyze the relationship of the MoCA score with the age, BMI, schooling length, and blood serum BDNF level. \**P* < 0.05, \*\**P* < 0.01.

**Table 5**

Correlation analysis of the serum BDNF level with the age, BMI, schooling length, and sleep structure.

| Indexes             | <i>r</i> | <i>P</i> |
|---------------------|----------|----------|
| Age                 | 0.072    | 0.653    |
| BMI                 | -0.020   | 0.900    |
| Length of schooling | -0.010   | 0.952    |
| AHI (times/h)       | -0.607** | 0.000    |
| LSO (%)             | 0.566**  | 0.000    |
| S1+S2 (%)           | -0.768** | 0.000    |
| S3+S4 (%)           | 0.778**  | 0.000    |
| REM (%)             | 0.575**  | 0.000    |

## 4. Discussion

The mechanism of cognitive impairment in OSAHS patients is unclear. Animal experiments showed that BDNF mRNA expression in the hippocampus especially in the CA2 and CA3 areas are closely associated with learning and memory<sup>[15]</sup>. BDNF and its receptor are involved in long-term potentiation by regulating the cholinergic system of the basal forebrain, synaptic transmission, and synaptic plasticity, as well as by affecting learning and memory<sup>[16]</sup>. Researchers

argued that reduced BDNF production in the cortex and hippocampus can lead learning and memory degradation<sup>[17]</sup>.

Compared with the control group, the AHI of the OSAHS group was significantly higher, the LSO was significantly decreased, shallow sleep (S1+S2) was significantly extended, and both slow wave sleep (S3+S4) and REM were significantly reduced. These results suggested that the OSAHS patients had nocturnal hypoxemia and sleep disturbance. The OSAHS patients had poorer cognitive function than the control group. Their executive function, calculation, memory, and abstraction were also significantly decreased compared with the control group. These results well agreed with previous results<sup>[18,19]</sup>.

The serum BDNF level of the subjects was detected using ELISA. Considering cognitive function and serum BDNF level were influenced by sex, age, education degree, other diseases and so on, abovementioned factors were controlled for subjects in this study. The OSAHS patients had significantly decreased serum BDNF levels compared with the controls. This finding suggested that the synthesis and release of BDNF in the OSAHS patients were inhibited. This result was similar to that obtained by Wang *et al*<sup>[10]</sup>. Further analysis on the relationship between cognitive function and the serum BDNF level was performed. The serum BDNF level was significantly positively correlated with the total MoCA score as well as the scores of executive function, memory, and abstraction. Thus, a higher serum BDNF level corresponded to better cognitive function, executive function, memory, and abstraction. These results are consistent with those obtained by previous researchers<sup>[20]</sup>. Although references on the correlation between BDNF and OSAHS are limited, the close correlation between BDNF and cognition was proved in several studies on cognitive deficit in AD, ARCD, and type 2 DM. It is reported that the serum and cerebrospinal fluid BDNF levels of AD patients are significantly decreased compared with controls, and decrease with age in healthy individuals<sup>[21,22]</sup>. McLay *et al*<sup>[23]</sup> used a Morris water maze to test the memory and learning ability of rats. They found that aged rats have poorer memories and learning abilities than younger rats, and the cognitive function of rats is negatively correlated with the neuron density and BDNF gene expressed in the hippocampus. Other studies suggested that the serum and plasma BDNF levels of type 2 DM patients are lower than those of healthy people, and this variety is correlated with their cognitive degradation. Researchers suggested that adequate blood BDNF concentrations can stop cognitive impairment<sup>[24–27]</sup>. Based on previous studies and the present one, we supposed that the decrease in serum BDNF is one of the biochemical mechanisms of cognitive deficit in OSAHS patients.

To determine the reason for the declined serum BDNF level of OSAHS patients, we analyzed the relationship between the serum BDNF level and sleep structure of the

subjects. We found that the serum BDNF level was closely negatively correlated with the time percentages of stages 1 and 2 sleeps, but closely positively correlated with the time percentages of stage 3 and 4 sleep, as well as with REM. A longer time of shallow sleep or shorter time of slow wave sleep corresponded to lower serum BDNF levels. Thus, extending shallow sleep or shortening deep sleep and REM sleep may lead to declined serum BDNF levels in OSAHS patients. Hiroyoshi *et al*<sup>[28–30]</sup> reported that the cerebellar and brainstem BDNF levels of rats decline after 6 h of REM sleep deprivation. They suggested that a shortened REM time explains the reduction in BDNF secretion and release. Ugo *et al*<sup>[30]</sup> proved that the synthesis and release of BDNF occur in the brain during the period of slow wave sleep. After exogenous BDNF is injected into the cerebral hemispheres of rats, the animals can more deeply sleep than untreated rats. They believed that BDNF is important in slow wave sleep and both conditions regulate each other. Based on our study, we suggest that the decreased serum BDNF levels of OSAHS patients is due to a sleep structural disorder, particularly, significantly shortened slow wave and REM sleep, which lead to cognitive dysfunction.

Nocturnal hypoxemia and the serum BDNF level were correlated. We found that the serum BDNF level was significantly negatively correlated with the AHI, but significantly positively correlated with the LSO. Thus, a higher severity of apnea/hyponea in OSAHS patients resulted in lower serum BDNF levels. This finding suggested that the serum BDNF level of OSAHS patients was closely related to the severity of nocturnal hypoxemia. Samantha *et al*<sup>[31]</sup> found that intermittent hypercapnic hypoxia upregulated apoptotic promoters and downregulated apoptotic inhibitors in the developing hippocampus of a piglet. Based on our findings, we speculate that nocturnal hypoxemia can promote neuronal apoptosis in the cerebral regions that are closely related with cognition, resulting in lower-than-normal levels of BDNF and its receptor.

In conclusion, the decrease in the serum BDNF levels of OSAHS patients is probably one of the mechanisms that lead to cognitive impairment as a result of nocturnal hypoxemia as well as deprived slow wave sleep and REM.

### Conflict of interest statement

We declare that we have no conflict of interest.

### Acknowledgements

This study was supported by the Science and Technology Bureau of Hunan Province, People's Republic of China (grant number 2011-FJ3192).

## References

- [1] Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM. Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. *J Alzheimer's Dis* 2003; **5**(3): 209–228.
- [2] Kingshott RN, Cosway RJ, Deary IJ, Douglas NJ. The effect of sleep fragmentation on cognition processing using computerized topographic brain mapping. *J Sleep Res* 2000; **9**(4): 353–357.
- [3] Bruin PF, Bagnato MC. Cognitive impairment in obstructive sleep apnea syndrome. *J Bras Pneumol* 2010; **36**(Suppl 2): 32–37.
- [4] Hashimoto K. BDNF variant linked to anxiety-related behaviors. *Bioessay* 2007; **29**(2): 116–119.
- [5] Bartkowska K, Turlejski K, Djavadian RL. Neurotrophins and their receptors in early development of the mammalian nervous system. *Acta Neurobiol Exp(Wars)* 2010; **70**(4): 454–467.
- [6] Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. *J Neural Transm* 2006; **113**(9): 1217–1224.
- [7] Li Y, Ji YJ, Jiang H, Liu DX, Zhang Q, Fan SJ, et al. Effects of unpredictable chronic stress on behavior and brain-derived neurotrophic factor expression in CA3 subfield and dentate gyrus of the hippocampus in different aged rats. *Chin Med J (Engl)* 2009; **122**(13): 1564–1569.
- [8] Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci USA* 2010; **107**(52): 22687–22692.
- [9] Arentoft A, Sweat V, Starr V, Oliver S, Hassenstab J, Bruehl H, et al. Plasma BDNF is reduced among middle-aged and elderly women with impaired insulin function: evidence of a compensatory mechanism. *Brain Cogn* 2009; **71**(2): 147–152.
- [10] Wang Y, Wang JJ, Zhao MQ, Liu SM, Li YZ. Changes of serum brain-derived neurotrophic factor in children with obstructive sleep apnoea-hypopnoea syndrome following adenotonsillectomy. *J Int Med Res* 2010; **38**(6): 1942–1951.
- [11] Hu F. Effects of nasal continuous positive airway pressure short-term treatment on the cognitive function, serum insulin-like growth factor-1 and brain-derived neurotrophic factor in patients with obstructive sleep apnea-hypopnea syndrome, Master Thesis. Changsha: Central South University; 2007.
- [12] Staats R, Stoll P, Zingler D, Virchow JC, Lommatzsch M. Regulation of brain-derived neurotrophic factor (BDNF) during sleep apnoea treatment. *Thorax* 2005; **60**(8): 688–692.
- [13] Iber C, Meolia A, Coleman J. Clinical Practice Review Committee, American Academy of Sleep Medicine. Definitions of respiratory events in sleep-disordered breathing. *Sleep Med* 2002; **3**(5): 451.
- [14] Zhang X. *Modern sleep medicine*. Beijing: People's Military Medical Press; 2007, p. 315.
- [15] Zafra F, Hengerer B, Leibrock J, Thoenen H, Lindholm D. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. *EMBO J* 1990; **9**(11): 3545–3550.
- [16] Knipper M, Berzaghi MP, Blochl A. Positive feed back between acetyl choline and the neurotrophins nerve growth factor and brain derived neurotrophic factor in the rat hippocampus. *Eur J Neurosci* 1994; **6**(2): 668–671.
- [17] Jiang QS, Liang ZL, Wu MJ, Feng L, Liu LL, Zhang JJ. Reduced brain-derived neurotrophic factor expression in cortex and hippocampus involved in the learning and memory deficit in molarless SAMP8 mice. *Chin Med J(Engl)* 2011; **124**(10): 1540–1544.
- [18] Hoy CJ, Vennelle M, Kingshott RN, Engleman HM, Douglas NJ. Can intensive support improve continuous positive airway pressure use in patients with the sleep apnea/hypopnea syndrome? *Am J Respir Crit Care Med* 1999; **159**: 1096–1100.
- [19] Weaver T, Maislin G, Schwab R. Perception of OSA risks and benefits and volition to use CPAP. *Am J Respir Crit Care Med* 2001; **163**(Suppl 5): A838.
- [20] Hui X, Yung WH. Chronic intermittent hypoxia-induced deficits in synaptic plasticity and neurocognitive functions: a role for brain-derived neurotrophic factor. *Acta Pharmacologica Sinica* 2012; **33**: 5–10.
- [21] Lee JG, Shin BS, You YS, Kim JE, Yoon SW, Jeon DW, et al. Decreased serum brain-derived neurotrophic factor levels in elderly Korean with dementia. *Psychiatry Investig* 2009; **6**(4): 299–305.
- [22] Chakraborty A, Panja S, Bhattacharjee I, Chandra G, Hati A. A longitudinal study of neurocysticercosis through CT scan of the brain. *Asian Pac J Trop Dis* 2011; **1**(3): 206–208.
- [23] Oliver von Bohlen und Halbach. Involvement of BDNF in age-dependent alterations in the hippocampus. *Front Aging Neurosci* 2010; **2**: 36.
- [24] Kumar A, Biswas UK, Nagtilak S, Ramiah S. Lipid ratio useful indicator in predicting risk of myocardial infarction in elderly normolipidemic patients: a report from a multi center study. *Asian Pac J Trop Dis* 2011; **1**(2): 123–126.
- [25] Scuri M, Samsell L, Piedimonte G. The role of neurotrophins in inflammation and allergy. *Inflamm Allergy Drug Targets* 2010; **9**(3): 173–180.
- [26] Laske C, Stellos K, Hoffmann N, Stransky E, Straten G, Eschweiler GW, et al. Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. *Int J Neuropsychopharmacol* 2011; **14**(3): 399–404.
- [27] Gupta V, Chhina D, Kaushal RK, Gupta R. Tuberculous brain abscess—Case Report. *Asian Pac J Trop Dis* 2012; **2**(5): 419–420.
- [28] Hiroyoshi S, Daisuke S, Kei Y, Kyoji M, Yusuke M. Differential effect of short-term REM sleep deprivation on NGF and BDNF protein levels in the rat brain. *Brain Res* 2000; **877**(2): 387–390.
- [29] Shilpa Khullar, Rashmi Babbar. Presbycusis and auditory brainstem responses: a review. *Asian Pac J Trop Dis* 2011; **1**(2): 150–157.
- [30] Ugo F, Vladysav VV, Aaron BN, Giulio T, Chiara C. A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. *J Neur* 2008; **28**(15): 4088–4095.
- [31] Tang S, Machaalani R, Waters KA, Fanous AM. Intermittent hypercapnic hypoxia induced protein changes. *Neurochem Res* 2009; **34**: 2215–2225.